Romosozumab (Evenity)

2 shared conditions · 13 outcomes

Teriparatide (brand name Forteo) is a recombinant form of the first 34 amino acids of human parathyroid hormone (PTH 1-34). It was FDA-approved in November 2002 as the first anabolic agent for osteoporosis treatment. Unlike antiresorptive drugs, teriparatide stimulates new bone formation. It is indicated for postmenopausal women and men with osteoporosis at high fracture risk, and for glucocorticoid-induced osteoporosis.

2 shared conditions · 14 outcomes

Denosumab is a fully human monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor-κB ligand), the key mediator of osteoclast formation and activity. FDA-approved in 2010 for osteoporosis (Prolia, 60mg every 6 months) and bone metastases (Xgeva, 120mg monthly). The landmark FREEDOM trial demonstrated significant reductions in vertebral, hip, and nonvertebral fractures, with benefits sustained up to 10 years in extension studies.

2 shared conditions · 14 outcomes

Calcitonin salmon is a 32-amino acid peptide hormone analog used for postmenopausal osteoporosis and hypercalcemia. FDA-approved since 1975 as nasal spray (200 IU daily) and injection (100 IU daily). A-GRADE evidence: PROOF trial showed 33% reduction in vertebral fractures at 200 IU daily. A-GRADE for bone turnover marker reduction and acute fracture pain relief. B-GRADE for BMD increase and chronic bone pain. Has unique analgesic properties making it useful for acute osteoporotic fracture pain. Salmon calcitonin has 40-50x greater potency than human calcitonin. PRESCRIPTION ONLY - second-line osteoporosis treatment after bisphosphonates.